The defining feature of tuberculosis is the long period of clinical latency during which the causative agent, Mycobacterium tuberculosis (Mtb), grows slowly if at all. It is difficult to overstate the importance of this quiescent behavior, as it likly underlies both the chronic nature of the infection and the relative ineffectiveness of antibiotics. Despite the growing recognition that quiescence is a relatively common microbial response to stress, the physiological state of these slowly- or non-replicating cells has remained enigmatic. To investigate the transition to quiescence, we identified both the genes required for the growth arrest and long-term survival of Mtb during stress-induced stasis, and the metabolic alterations that accompany this transition. Based on these complementary studies, we propose a regulatory cascade that senses host-derived stress, slows bacterial growth, and remodels metabolism for long-term stasis. In this project we will combine high-throughput genetic and biochemical methods to define the structure of this regulatory pathway and determine its ultimate role in promoting bacterial persistence and determining drug efficacy in vivo. We will then characterize the metabolic alterations that are required for the adaptation to quiescence and determine which of these are necessary for survival during stasis. Our goal is to devise new strategies to accelerate tuberculosis therapy through the identification and characterization of cellular pathways that are required for maintaining the quiescent state.

Public Health Relevance

Tuberculosis remains a devastating disease that affects much of the world and is responsible approximately two million deaths every year. Effective treatment of fully drug-susceptible strains of M. tuberculosis requires the administration of multiple antibiotics for at least six months. It has been estimated that reducing treatment duration to two months could both prevent millions of TB cases and slow the emergence of drug resistance. Both the persistence of latent infection and the relatively poor efficacy of antibiotics have been attributed to the presence of slowly- or non-replicating populations of the causative agent, Mycobacterium tuberculosis (Mtb), which are tolerant to both immune insults and antibiotic treatment. We have begun to define the physiology of these drug-tolerant bacterial populations and have demonstrated that disrupting this quiescence program can dramatically improve the efficacy of antibiotics during infection. The proposed project will define the pathways responsible for initiating and maintaining the quiescent state. This information can be used to identifying targets of a new generation of synergistic therapies that could shorten the duration of TB therapy.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
2R01AI064282-06A1
Application #
8578516
Study Section
Bacterial Pathogenesis Study Section (BACP)
Program Officer
Lacourciere, Karen A
Project Start
2005-04-01
Project End
2018-04-30
Budget Start
2013-05-10
Budget End
2014-04-30
Support Year
6
Fiscal Year
2013
Total Cost
$391,275
Indirect Cost
$156,275
Name
University of Massachusetts Medical School Worcester
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
603847393
City
Worcester
State
MA
Country
United States
Zip Code
01655
Murphy, Kenan C; Nelson, Samantha J; Nambi, Subhalaxmi et al. (2018) ORBIT: a New Paradigm for Genetic Engineering of Mycobacterial Chromosomes. MBio 9:
Rittershaus, Emily S C; Baek, Seung-Hun; Krieger, Inna V et al. (2018) A Lysine Acetyltransferase Contributes to the Metabolic Adaptation to Hypoxia in Mycobacterium tuberculosis. Cell Chem Biol 25:1495-1505.e3
Köster, Stefan; Klevorn, Thais; Papavinasasundaram, Kadamba et al. (2018) Consequence of enhanced LC3-trafficking for a live, attenuated M. tuberculosis vaccine. Vaccine 36:939-944
Olive, Andrew J; Smith, Clare M; Kiritsy, Michael C et al. (2018) The Phagocyte Oxidase Controls Tolerance to Mycobacterium tuberculosis Infection. J Immunol 201:1705-1716
Logsdon, Michelle M; Ho, Po-Yi; Papavinasasundaram, Kadamba et al. (2017) A Parallel Adder Coordinates Mycobacterial Cell-Cycle Progression and Cell-Size Homeostasis in the Context of Asymmetric Growth and Organization. Curr Biol 27:3367-3374.e7
DeJesus, Michael A; Nambi, Subhalaxmi; Smith, Clare M et al. (2017) Statistical analysis of genetic interactions in Tn-Seq data. Nucleic Acids Res 45:e93
García-Fernández, Julia; Papavinasasundaram, Kadamba; Galán, Beatriz et al. (2017) Unravelling the pleiotropic role of the MceG ATPase in Mycobacterium smegmatis. Environ Microbiol 19:2564-2576
Köster, Stefan; Upadhyay, Sandeep; Chandra, Pallavi et al. (2017) Mycobacterium tuberculosis is protected from NADPH oxidase and LC3-associated phagocytosis by the LCP protein CpsA. Proc Natl Acad Sci U S A 114:E8711-E8720
Rock, Jeremy M; Hopkins, Forrest F; Chavez, Alejandro et al. (2017) Programmable transcriptional repression in mycobacteria using an orthogonal CRISPR interference platform. Nat Microbiol 2:16274
Mishra, Bibhuti B; Lovewell, Rustin R; Olive, Andrew J et al. (2017) Nitric oxide prevents a pathogen-permissive granulocytic inflammation during tuberculosis. Nat Microbiol 2:17072

Showing the most recent 10 out of 47 publications